论文部分内容阅读
目的：探讨静脉溶栓治疗不稳定型心绞痛（UAP）的临床疗效及安全性。方法：选择60例UAP患者随机分成治疗组和对照组，治疗组在对照组的严格内科常规药物治疗基础上静脉使用尿激酶20万单位，每日1次，连用5日；观察两组心绞痛发作及心电图变化，1周后评定疗效。结果：治疗组显效率50％，总有效率93％；对照组显效率23％，总有效率73％；两组比较显效及总有效率有统计学显著性差异（P ＜0．05）；治疗组出血发生率为17％，对照组率为7％。结论：在设备技术相对薄弱的基层医院，对于顽固的、经严格内科药物治疗无效的心绞痛，使用溶栓疗法不失为有益的可供选择的治疗手段。使用简便安全，不良反应少。
Objective: To investigate the clinical efficacy and safety of intravenous thrombolysis in the treatment of unstable angina pectoris (UAP). Methods: Sixty patients with UAP were randomly divided into treatment group and control group. In the control group, 200 000 units of urokinase were intravenously administered on the basis of strict routine medical treatment in the control group, once daily for 5 days. Angina pectoris And ECG changes, 1 week after the assessment of efficacy. Results: The effective rate of the treatment group was 50% and the total effective rate was 93%. The effective rate of the control group was 23% and the total effective rate was 73%. There was a statistically significant difference between the two groups (P <0.05). The bleeding rate was 17% in the treatment group and 7% in the control group. CONCLUSIONS: In primary hospitals with relatively poor equipment technology, the use of thrombolytic therapy is a useful alternative treatment of refractory angina pectoris that is refractory to rigorous medical treatment. Easy to use and safe, less adverse reactions.